Mechanisms underlying the anti-proliferative actions of adiponectin in human breast cancer cells, MCF7-dependency on the cAMP/protein Kinase-A pathway

Nutrition and Cancer

Volumn 63, Issue 1, 2011, Pages 80-88

  Li, Gang ^a   Cong, Li ^a   Gasser, Jessica ^b   Zhao, Jessica ^b   Chen, Ke ^b   Li, Fanghong ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLIN D1; CYCLIN E; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA; PROTEIN KINASE B; SOMATOMEDIN C; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ADIPONECTIN; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIN D1; CYCLINS; FEMALE; HUMANS; RECEPTORS, ADIPONECTIN; SIGNAL TRANSDUCTION;

EID: 78751539819     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635581.2010.516472     Document Type: Article

References (47)

1. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, and Viale G: Breast cancer. Lancet 365, 1727-1741, 2005.
2. Singletary SE: Rating the risk factors for breast cancer. Ann Surg 237, 474-482, 2003.
3. Willett WC, Dietz WH, and Colditz GA: Guidelines for healthy weight. N Engl J Med 341, 427-434, 1999.
4. Loi S,Milne RL, FriedlanderML, McCredie MR, Giles GG, et al.: Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 14, 1686-1691, 2005.
5. Newman SC, Lees AW, and Jenkins HJ: The effect of body mass index and oestrogen receptor level on survival of breast cancer patients. Int J Epidemiol 26, 484-490, 1997.
6. Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med 354, 270-282, 2006.
7. Laban C, Bustin SA, and Jenkins PJ: The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab 14, 28-34, 2003.
8. Bohlke K, Cramer DW, Trichopoulos D, and Mantzoros CS: Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 9, 570-573, 1998.
9. Iyengar P, Combs TP, Shah SJ, Gouon-Evans V, Pollard JW, et al.: Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and protooncogene stabilization. Oncogene 22, 6408-6423, 2003.
10. Lautenbach A, Budde A, Wrann CD, Teichmann B,Vieten G, et al.: Obesity and the associated mediators leptin, estrogen and IGF-I enhance the cell proliferation and early tumorigenesis of breast cancer cells. Nutr Cancer 61, 484-491, 2009.
11. Kadowaki T and Yamauchi T: Adiponectin and adiponectin receptors. Endocr Rev 26, 439-451, 2005.
12. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, et al.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86, 1930-1935, 2001.
13. Korner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, et al.: Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 92, 1041-1048, 2007.
14. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, et al.: Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89, 1102-1107, 2004.
15. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, et al.: Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9, 5699-5704, 2003.
16. Otake S, Takeda H, Suzuki Y, Fukui T, Watanabe S, et al.: Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res 11, 3642-3646, 2005.
17. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, et al.: Plasma adiponectin levels and endometrial cancer risk in pre-and postmenopausal women. J Clin Endocrinol Metab 92, 255-263, 2007.
18. Dos Santos E, Benaitreau D, Dieudonne MN, Leneveu MC, Serazin V, et al.: Adiponectin mediates an antiproliferative response in human MDAMB 231 breast cancer cells. Oncol Rep 20, 971-977, 2008.
19. de Assis S, Wang M, Goel S, Foxworth A, Helferich W, et al.: Excessive weight gain during pregnancy increases carcinogen-induced mammary tumorigenesis in Sprague-Dawley and lean and obese Zucker rats. J Nutr 136, 998-1004, 2006.
20. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, et al.: Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 345, 271-279, 2006.
21. Treeck O, Lattrich C, Juhasz-Boess I, Buchholz S, Pfeiler G, et al.: Adiponectin differentially affects gene expression in human mammary epithelial and breast cancer cells. Br J Cancer 99, 1246-1250, 2008.
22. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, et al.: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMPactivated protein kinase. Nat Med 8, 1288-1295, 2002.
23. Luo Z, Saha AK, Xiang X, and Ruderman NB: AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26, 69-76, 2005.
24. Rattan R, Giri S, Singh AK, and Singh I: 5-Aminoimidazole-4-carboxamide- 1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280, 39582-39593, 2005.
25. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, et al.: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102, 1296-1301, 2000.
26. Kobashi C, Urakaze M, Kishida M, Kibayashi E, Kobayashi H, et al.: Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 97, 1245-1252, 2005.
27. Chin KV, Yang WL, Ravatn R, Kita T, Reitman E, et al.: Reinventing the wheel of cyclic AMP: novel mechanisms of cAMP signaling. Ann NY Acad Sci 968, 49-64, 2002.
28. Starzec AB, Spanakis E, Nehme A, Salle V, Veber N, et al.: Proliferative responses of epithelial cells to 8-bromo-cyclic AMP and to a phorbol ester change during breast pathogenesis. J Cell Physiol 161, 31-38, 1994.
29. Manna PP and Frazier WA: CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. Cancer Res 64, 1026-1036, 2004.
30. Karey KP and Sirbasku DA: Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res 48, 4083-4092, 1988.
31. Murray AW: Recycling the cell cycle: cyclins revisited. Cell 116, 221-234, 2004.
32. Keyomarsi K, Tucker SL, and Bedrosian I: Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. NatMed 9, 152, 2003.
33. Moschos SJ andMantzoros CS: The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63, 317-332, 2002.
34. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, et al.: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762-769, 2003.
35. Carmina E, Orio F, Palomba S, Longo RA, Cascella T, et al.: Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 119, 351-356, 2006.
36. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, et al.: Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 101, 2476-2481, 2004.
37. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, et al.: Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK-and COX-2-dependent mechanisms. Nat Med 11, 1096-1103, 2005.
38. Stork PJ and Schmitt JM: Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12, 258-266, 2002.
39. L'Allemain G, Lavoie JN, Rivard N, Baldin V, and Pouyssegur J: Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts. Oncogene 14, 1981-1990, 1997.
40. Davies SP, Reddy H, Caivano M, and Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351, 95-105, 2000.
41. Yin W, Mu J and Birnbaum MJ: Role of AMP-activated protein kinase in cyclic AMP-dependent lipolysis In 3T3-L1 adipocytes. J Biol Chem 278, 43074-43080, 2003.
42. Hutchinson DS, Chernogubova E, Dallner OS, Cannon B, and Bengtsson T: Beta-adrenoceptors, but not alpha-adrenoceptors, stimulate AMP-activated protein kinase in brown adipocytes independently of uncoupling protein-1. Diabetologia 48, 2386-2395, 2005.
43. Calle EE and Thun MJ: Obesity and cancer. Oncogene 23, 6365-6378, 2004.
44. Kolonel LN, Altshuler D, and Henderson BE: The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer 4, 519-527, 2004.
45. Leyva F, Godsland IF, Ghatei M, Proudler AJ, Aldis S, et al.: Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 18, 928-933, 1998.
46. Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, et al.: Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 14, 656-661, 2005.
47. Liu YM, Lacorte JM, Viguerie N, Poitou C, Pelloux V, et al.: Adiponectin gene expression in subcutaneous adipose tissue of obesewomen in response to short-term very low calorie diet and refeeding. J Clin Endocrinol Metab 88, 5881-5886, 2003.